- Home
- CBL vs SVRA Comparison
CBL vs SVRA Comparison
Compare CBL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBL
- SVRA
- Stock Information
- Founded
- CBL 1978
- SVRA N/A
- Country
- CBL United States
- SVRA United States
- Employees
- CBL N/A
- SVRA N/A
- Industry
- CBL Real Estate Investment Trusts
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CBL Real Estate
- SVRA Health Care
- Exchange
- CBL Nasdaq
- SVRA Nasdaq
- Market Cap
- CBL 813.3M
- SVRA 739.1M
- IPO Year
- CBL 1993
- SVRA N/A
- Fundamental
- Price
- CBL $27.25
- SVRA $2.98
- Analyst Decision
- CBL
- SVRA Buy
- Analyst Count
- CBL 0
- SVRA 6
- Target Price
- CBL N/A
- SVRA $10.17
- AVG Volume (30 Days)
- CBL 103.4K
- SVRA 1.6M
- Earning Date
- CBL 11-11-2024
- SVRA 11-12-2024
- Dividend Yield
- CBL 5.87%
- SVRA N/A
- EPS Growth
- CBL N/A
- SVRA N/A
- EPS
- CBL 1.01
- SVRA N/A
- Revenue
- CBL $523,580,000.00
- SVRA N/A
- Revenue This Year
- CBL N/A
- SVRA N/A
- Revenue Next Year
- CBL N/A
- SVRA N/A
- P/E Ratio
- CBL $26.97
- SVRA N/A
- Revenue Growth
- CBL N/A
- SVRA N/A
- 52 Week Low
- CBL $20.97
- SVRA $2.83
- 52 Week High
- CBL $28.50
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- CBL 55.53
- SVRA 31.47
- Support Level
- CBL $25.92
- SVRA $3.50
- Resistance Level
- CBL $28.50
- SVRA $4.30
- Average True Range (ATR)
- CBL 0.57
- SVRA 0.29
- MACD
- CBL -0.04
- SVRA -0.05
- Stochastic Oscillator
- CBL 51.55
- SVRA 10.24
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a U.S.-based real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.